Indivior PLC (INDV)

Market Cap	1.70B
Revenue (ttm)	1.17B
Net Income (ttm)	-62.00M
Shares Out	124.77M
EPS (ttm)	-0.48
PE Ratio	n/a
Forward PE	10.96
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,064,121
Open	13.50
Previous Close	13.43
Day's Range	13.44 - 13.96
52-Week Range	7.33 - 17.09
Beta	0.25
Analysts	Strong Buy
Price Target	14.50 (+5.92%)
Earnings Date	Jul 24, 2025

About INDV

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX T...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 1,051
• Stock Exchange: NASDAQ
• Ticker Symbol: INDV
• Website: https://www.indivior.com

Analyst Forecast

According to 2 analysts, the average rating for INDV stock is "Strong Buy." The 12-month stock price forecast is $14.5, which is an increase of 5.92% from the latest price.

Price Target

$14.5

(5.92% upside)

Analyst Consensus: Strong Buy